Colorectal cancer (CRC) is one of the most common malignancies; approximately 1.4 million patients are diagnosed with CRC each year worldwide.
but the exact pathogenesis is still unclear. 5 Therefore, further study of the molecular mechanisms of CRC is essential to ease the burden of the disease.
Only approximately 1.5% of genes in the human genome can encode proteins, and most genes are transcribed into noncoding RNAs (ncRNA). 6 Noncoding RNAs can be divided into short ncRNAs and long ncRNAs (lncRNA) according to their length (less than or greater than 200 nt). Long ncRNA is the most common and most versatile class. 7 Long ncRNA lacks a significant ORF and is widely present in the nucleus and cytoplasm. 8, 9 It does not participate in protein coding. 10 Recent studies have shown that lncRNA plays a critical role in carcinogenesis. For example, upregulation of SNHG6 regulates ZEB1 expression by competitively binding microRNA-101-3p
and interacting with UPF1 in hepatocellular carcinoma. 11 Our previous studies also reported that lncRNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703
expression. 12 However, the function of lncRNAs in human CRC remains largely unknown. In this study, we identified MAPKAPK5-AS1, a novel lncRNA previously mentioned in published reports, 13 
| MATERIAL S AND ME THODS

| Clinical specimens
From January 2015 to December 2018, 50 pairs of matched tumor tissues and corresponding normal tissues were collected from CRC patients undergoing surgical treatment in the Second Affiliated
Hospital of Nanjing Medical University (Nanjing, China). None of the patients received any local or systemic treatment before surgery.
The pathological stage, grade, and nodal status were appraised by an experienced pathologist. All experiments were approved by the research ethics committee of Nanjing Medical University. Written informed consent was obtained from all patients.
| Cell culture
The CRC cell lines HCT116, SW480, HT-29, and DLD-1, and the nor- 
| RNA isolation and qPCR assays
Total RNA was extracted from tissues or cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA quantity and quality were determined by NanoDrop2000c (Thermo Fisher Scientific, Waltham, MA, USA).
For qRT-PCR, 1 μg RNA was reverse transcribed into cDNA using a reverse transcription kit (Takara, Dalian, China). Quantitative PCR assays were carried out on an ABI 7500 (Carlsbad, CA, USA).
Data were normalized to GAPDH. The primer sequences were:
MAPKAPK5-AS1, forward AAGCCCGAGTCTGATGCTAA, and reverse CTGCACACCTCTTCTGGTCA; p21, forward GAGACTCT CAGGGTCGAAAACG, and reverse GGATTAGGGCTTCCTCTTGGA;
GAPDH, forward AGCCACATCGCTCAGACAC, and reverse GCCCAATACGACCAAATCC; and U6 forward ATTGGAACG ATACAGAGAAGATT, and reverse GGAACGCTTCACGAATTTG. The
ChIP-qPCR primers for p21 were: forward, CTGCCTCTGCTCAAT AATGTTCT; and reverse, GGAATTCACCTTCACACAGGC. Each sample was analyzed in triplicate.
| Cell transfection
Two individual MAPKAPK5-AS1 (MAPKAPK5-AS1 2# and 3#), si-EZH2, and 
| Cell proliferation assays
A cell proliferation assay was carried out with a CCK-8 assay kit 
| Flow cytometric analysis
| 5-Ethynyl-2′-deoxyuridine (EdU) analysis
| Cell apoptosis assay
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling was carried out with an apoptosis detection kit (Ribobio)
according to the manufacturer's instructions. A randomly selected field without significant necrosis in 10 high-power fields was assessed for TUNEL-positive cells. The index of TUNEL was calculated based on the number of total nuclei and cells with green nuclei. Each sample was analyzed in triplicate.
| Subcellular fractionation location
The separation of nuclear and cytosolic fractions was undertaken using the PARIS Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Each sample was analyzed in triplicate.
| Fluorescence in situ hybridization
SW480 cells were seeded in 24-well plates, fixed in 4% formaldehyde for 10 minutes, treated with PBS containing 0.5% Triton X-100, then washed 3 times with PBS. The prehybrid solution was added, then the probe-containing hybridization solution was added overnight. After washing with 4×, 2×, and 1× SSC, cells were stained with DAPI. The RNA FISH probe was designed and synthesized by Ribobio.
| RNA immunoprecipitation (RIP)
We followed the manufacturer's protocol using the EZMagna RIP kit 
| Chromatin immunoprecipitation
| Western blot assay
SW480 cells were harvested, and proteins were extracted from the transfected cells and quantified using a 12% polyacrylamide gradient SDS gel as previously described. Quantification was undertaken using a density assay (Quantity One software; Bio-Rad, Hercules, CA, USA) using ECL chromogenic substrate. A GAPDH Ab (#2118; Cell Signaling Technology, Boston, MA, USA) was used as a control. Anti-p21 was purchased from Abcam.
| Nude mouse tumor formation experiment
To 
| Immunohistochemistry (IHC)
Xenograft tumor tissue samples were immunostained with H&E and Ki67. Anti-Ki67 was from Santa Cruz Biotechnology (Dallas, TX, USA). The IHC staining results were independently scored by the author and a pathologist to minimize subjectivity and then compared, and the final comprehensive results were obtained.
| Statistical analysis
Statistical analysis was carried out using SPSS software (SPSS, Chicago, IL, USA Statistical significance was assigned at *P < .05 or **P < .01. All experiments were carried out at least 3 times, in triplicate samples. Figure 1B ), larger tumor (P = .004; Figure 1C ), and positive lymph node status (P = .001; Figure 1D ).
Kaplan-Meier survival analysis and log-rank tests show survival time for cases with high MAPKAPK5-AS1 expression was below those with low MAPKAPK5-AS1 expression ( Figure 1E ). However, several other clinical parameters were found not to be significantly associated with MAPKAPK5-AS1 expression (Table 1) . Therefore, we speculate that the expression of MAPKAPK5-AS1 could be related to CRC. The TUNEL assay for detecting apoptosis was also consistent with the above results ( Figure 3C ). These findings suggest that MAPKAPK5-AS1 might be closely related to the proliferation of CRC cells.
| MAPKAPK5-
F I G U R E 1 MAPKAPK5-AS1 is upregulated in human colorectal cancer (CRC) tissues and is significantly correlated with larger tumor size, advanced TNM stage, lymph node metastasis, and poor prognosis. A, Relative expression of MAPKAPK5-AS1 in CRC tissues (n = 50) compared with the corresponding non-tumor tissues (n = 50); the patients were classified into two groups according to the median level of MAPKAPK5-AS1. MAPKAPK5-AS1 expression was examined by quantitative RT-PCR (qRT-PCR) and normalized to GAPDH expression. B-D, MAPKAPK5-AS1 expression was significantly higher in patients with larger tumor size, higher pathological stage, and lymph node metastasis. E, Kaplan-Meier overall survival curves according to MAPKAPK5-AS1 expression level. Cum., cumulative. F, MAPKAPK5-AS1 expression was assessed by qRT-PCR analysis in CRC cells (DLD-1, HCT116, HT29, and SW480) and the normal human colonic epithelial cell line (HCoEpiC). G, Quantitative PCR analysis of MAPKAPK5-AS1 expression levels following transfection of DLD-1 and SW480 cells with siRNAs against MAPKAPK5-AS1. Representative images and data based on 3 independent experiments. Bars: ± SD. **P < .01. siNC, negative control
| Knockdown of MAPKAPK5-AS1 inhibits CRC tumorigenesis in vivo
The statistical results of tumor volume changes showed that the tumor formation ability of the mice in the MAPKAPK5-AS1 knockdown group was significantly reduced and the growth rate was significantly slower compared to the control group ( Figure 4A ). As shown, qPCR con- 
| MAPKAPK5-AS1 overexpression induces promotion of CRC cell proliferation
To further explore the function of MAPKAPK5-AS1, we carried out an overexpression experiment in HCT116 cells. Both CCK-8
and EdU assays revealed that the viability of HCT116 cells transfected with pcDNA-MAPKAPK5-AS1 was significantly impaired compared with empty vector-treated cells ( Figure 5A -C).
The colony formation assays results showed that overexpression of MAPKAPK5-AS1 in HCT116 cells significantly promoted cell colony formation ( Figure 5D ). These findings indicated that MAPKAPK5-AS1 promoted CRC cell proliferation.
| MAPKAPK5-AS1 promotes CRC cell proliferation by partially binding histone EZH2 and subsequently inhibiting expression of target gene p21
To investigate the mechanism of MAPKAPK5-AS1 in CRC, we first analyzed its distribution in CRC cells and found that MAPKAPK5-AS1
is mainly located in the nucleus ( Figure 6A,B) , which means that MAPKAPK5-AS1 might be involved in transcriptional regulation. We used qRT-PCR to detect the 8 classical mRNA levels of proliferation-related genes after knocking down MAPKAPK5-AS1
(p15, p21, p27, p57, Bcl-2, Bax, KLF-2, and Trail; Figure 6C ). The results showed that, compared with the control group, p21 mRNA levels were changed to varying degrees after knockdown of MAPKAPK5-AS1 in SW480 and DLD-1 cells ( Figure 6D ). 
| p21 is potentially involved in the oncogenic function of MAPKAPK5-AS1
To verify the effect of p21 in CRC cells, p21 was knocked down in DLD-1 cells ( Figure 7A,B) . The CCK-8 and colony formation assays showed a significant change of CRC cell viability after p21 changed ( Figure 7C ).
Edu shows that si-p21 transfects DLD-1 cells ( Figure 7D ). These data indicate that inhibition of p21 promotes CRC cell proliferation. We also undertook colony formation assays to determine whether p21 is involved in MAPKAPK5-AS1-mediated CRC cell proliferation. DLD-1 cells were cotransfected with MAPKAPK5-AS1 and p21 shRNA. Colony formation assays showed that proliferation of DLD-1 cells cotransfected with sh-MAPKAPK5-AS1 and sh-p21 was increased compared to that in HUCCT1 cells treated with sh-MAPKAPK5-AS1 alone ( Figure 7E ). Bars: ± SD. *P < .05, **P < .01
Collectively, these data indicate that MAPKAPK5-AS1 partially promotes proliferation of CRC cells by p21 downregulation.
| D ISCUSS I ON
In recent years, more and more tumor-associated lncRNAs have been discovered. 18 A large number of published works have reported that these lncRNAs play an important role in multiple tumors. [19] [20] [21] [22] [23] Our previous research shows that lncRNA SNHG17
can promote the proliferation of CRC cells by inhibiting the expression of p57. 24 The high expression of lncRNA LL22NC03-N64E9.1 could predict poor prognosis in patients with colon cancer. 25 Long ncRNA SH3PXD2A-AS1 inhibits p21 expression by binding EZH2
to promote CRC cell proliferation. 26 Therefore, the discovery of new CRC-related lncRNAs is of great significance for further understanding the molecular mechanisms of CRC progression and providing clinical therapeutic targets. In this study, we analyzed 2 sources Representative Ki-67 protein levels in xenograft tumors as evaluated by immunohistochemistry. Representative images and data based on 3 independent experiments. Bars: ± SD, *P < .05, **P < .01
Many lncRNAs can regulate the expression of downstream target genes by forming complexes with RNA-binding proteins, [27] [28] [29] [30] then acts as an oncogene or a suppressor oncogene. [31] [32] [33] [34] [35] In this study, we found that knockdown of MAPKAPK5-AS1 in CRC cells could lead to changes in related downstream genes, including p15, p21, p27, p57, KLF2, and Trail. Among them, p21 has high basal expression abundance in CRC cells, which aroused our interest. We examine published reports and find that some lncRNAs can play an oncogene function by inhibiting p21 at the transcriptional level, such as lncRNA LUCAT1 36, 37 and lncRNA TUG1. [38] [39] [40] [41] In this study, We found that high expression of MAPKAPK5-AS1 in CRC tissue predicts poor prognosis in patients, and the activation F I G U R E 6 MAPKAPK5-AS1 partly silences p21 transcription by binding to enhancer of zeste homolog 2 (EZH2). A, Expression levels of MAPKAPK5-AS1 in cell nucleus and cytoplasm in DLD-1 and SW480 cells investigated by quantitative RT-PCR (qRT-PCR). U6 was used as a nuclear marker, and GAPDH was used as a cytosol marker. B, FISH analysis of the location of MAPKAPK5-AS1 (red) in the cytoplasm and nuclear fractions (blue) of SW480 cells. C, Eight classical mRNA expression levels D, Expression of p21 was determined after knockdown of MAPKAPK5-AS1 by qRT-PCR and western blot assays after transfection. E, RNA immunoprecipitation assays were carried out in DLD-1 and SW480 cells, and the coprecipitated RNA was subjected to qRT-PCR for MAPKAPK5-AS1. F, DUXAP10 was used as negative control. G, ChIP-qRT-PCR of EZH2 occupancy and H3K27me3 binding in the p21 promoter in DLD-1 and SW480 cells treated with si-MAPKAPK5-AS1 (48 hours) or the negative control (si-NC); IgG as negative control. H, ChIP-qRT-PCR of EZH2 occupancy and H3K27me3 binding in the p21 promoter in HCT116 cells treated with pcDNA-MAPKAPK5-AS1; IgG as negative control. I, qRT-PCR assays were used to determine the expression of EZH2 in DLD-1 cells after EZH2 knockdown. p21 expression was investigated in DLD-1 cells after knockdown of EZH2 through qRT-PCR and western blot assays. Representative images and data based on 3 independent experiments. Bars: ± SD, *P < .05, **P < .01 of the MAPKAPK5-AS1/EZH2/p21 regulatory axis plays an important role in the progression of CRC. However, this conclusion still needs to be expanded to verify clinical samples.
MAPKAPK5-AS1 could play another role in CRC and further research is needed. 
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